| Name
|
Endomorphin-2
|
| Other Name
|
Endomorphin2
|
| Sequence (Single letter abbreviations)
|
YPFF-NH2
|
| Sequence（Three letter abbreviations）
|
{TYR}{PRO}{PHE}{PHE}-NH2
|
| C-port
|
NH2
|
| Basic description
|
Endomorphin 2 is a potent, selective endogenous µ opioid receptor agonist. The physiological function of endomorphin-2 as a neurotransmitter or neuromodulator may cease through the rapid enzymatic process in the synapse of brain, as for other neuropeptides. Some results indicate that the administration of the endogenous µ-opioid ligand endomorphin-2, but not endomorphin-1, into the brain produces an antitussive effect via mainly naloxonazine-insensitive µ-opioid receptors, namely µ2-opioid receptors and partially kappa-opioid receptors.
|
| Solubility
|
Soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weight out a smaller portion of the contents.
|
| The molecular weight
|
571.670
|
| Chemical formula
|
C32H37N5O5
|
| The purity
|
> 95%
|
| Storage conditions
|
Store the peptide at -20°C. Keep container tightly closed. Store in a cool dry place.
|
| Annotation
|
Store at -20°C. Keep tightly closed.
|
| Documents
|
|
| Figures
|
|
| Reference
|
Viard E and Sapru HN, et al. Endomorphin-2 in the medial NTS attenuates the responses to baroreflex activation. Brain Res. Feb 2006; 1073-1074:365-373.
Botros M, et al. Endomorphin-1 and endomorphin-2 differentially interact with specific binding sites for substance P (SP) aminoterminal SP(1-7) in the rat spinal cord. Peptides. Apr 2006; 27(4):753-759.
Mizoguchi H, et al. Possible Involvement of Dynorphin A-(1-17) Release via {micro}1-Opioid Receptors in Spinal Antinociception by Endomorphin-2. J. Pharmacol. Exp. Ther. Apr 2006; 317(1): 362-368.
|
Endomorphin-2
